{"result": "(\"entity\"<|>INSULINA LISPRO<|>ORGANIZATION<|>Insulina lispro is a rapid-acting insulin analog that simulates the quick insulin response after meals in non-diabetic individuals.)\n##\n(\"entity\"<|>INSULINA ASPART<|>ORGANIZATION<|>Insulina aspart is a rapid-acting insulin analog that has a lower tendency to aggregate in the presence of zinc, allowing for faster absorption.)\n##\n(\"entity\"<|>INSULINA GLULISINA<|>ORGANIZATION<|>Insulina glulisina is a rapid-acting insulin analog that promotes the formation of monomers after subcutaneous administration, leading to quicker absorption.)\n##\n(\"entity\"<|>INSULINA REGULAR<|>ORGANIZATION<|>Insulina regular is a standard insulin solution that is transparent and contains insulin-zinc crystals, typically requiring administration before meals.)\n##\n(\"entity\"<|>MANUAL SEEN DE ENDOCRINOLOGÍA<|>ORGANIZATION<|>The Manual SEEN de Endocrinología is a reference guide for endocrinology, providing information on insulin types and their pharmacokinetics.)\n##\n(\"entity\"<|>DIABETES MELLITUS TIPO 1<|>EVENT<|>Diabetes Mellitus Tipo 1 is a condition that requires insulin treatment and can lead to complications such as hypoglycemia and weight gain.)\n##\n(\"relationship\"<|>INSULINA LISPRO<|>INSULINA REGULAR<|>Insulina lispro is compared to insulina regular in terms of pharmacokinetics, showing a faster peak concentration and action<|>7)\n##\n(\"relationship\"<|>INSULINA ASPART<|>INSULINA REGULAR<|>Insulina aspart is noted for its quicker absorption compared to insulina regular, making it more effective for postprandial glucose control<|>7)\n##\n(\"relationship\"<|>INSULINA GLULISINA<|>INSULINA REGULAR<|>Insulina glulisina is highlighted for its rapid action compared to insulina regular, allowing for better control of postprandial glucose levels<|>7)\n##\n(\"relationship\"<|>MANUAL SEEN DE ENDOCRINOLOGÍA<|>INSULINA LISPRO<|>The Manual SEEN de Endocrinología provides detailed information about insulina lispro and its pharmacokinetic profile<|>8)\n##\n(\"relationship\"<|>MANUAL SEEN DE ENDOCRINOLOGÍA<|>INSULINA ASPART<|>The Manual SEEN de Endocrinología includes insights on insulina aspart and its advantages over regular insulin<|>8)\n##\n(\"relationship\"<|>MANUAL SEEN DE ENDOCRINOLOGÍA<|>INSULINA GLULISINA<|>The Manual SEEN de Endocrinología discusses insulina glulisina and its benefits in insulin therapy<|>8)\n##\n(\"relationship\"<|>DIABETES MELLITUS TIPO 1<|>INSULINA LISPRO<|>Insulina lispro is used in the treatment of Diabetes Mellitus Tipo 1 to manage blood glucose levels<|>9)\n##\n(\"relationship\"<|>DIABETES MELLITUS TIPO 1<|>INSULINA ASPART<|>Insulina aspart is utilized in the management of Diabetes Mellitus Tipo 1 for better postprandial glucose control<|>9)\n##\n(\"relationship\"<|>DIABETES MELLITUS TIPO 1<|>INSULINA GLULISINA<|>Insulina glulisina is prescribed for patients with Diabetes Mellitus Tipo 1 to improve glycemic control<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: eder a la circulación sanguínea mientras no está en forma de dímero o de monómero.\nC. En términos de perfil farmacocinético, la insulina lispro, la insulina aspart y la insulina glulisina son similares.\nD. La insulina regular es una solución transparente de cristales de insulina-zinc.\n\nCOMENTARIO\n\nLos análogos de insulina de acción rápida (AIAR) intentan simular la respuesta insulinosecretora rápida, potente y de corta duración que ocurre tras la ingesta en los individuos no diabéticos (tabla 8). Actualmente disponemos de los AIAR lispro, aspart y glulisina. Estructuralmente, la insulina lispro presenta una inversión de los aminoácidos lisina y prolina que ocupan en la insulina regular humana (IRH) la posición B29 y B28, respectivamente. Esta inversión se traduce en un cambio conformacional que dificulta la formación de dímeros y hexámeros, incluso en presencia de zinc. En el caso de la insulina aspart, la sustitución de prolina por ácido aspártico (con cargas negativas) en la posición B28 da lugar a una menor tendencia, en presencia de zinc, a la agregación de las moléculas de insulina. Finalmente, en la insulina glulisina, la sustitución de asparagina por lisina en la posición B3 y de lisina por ácido glutámico en la posición B29 favorece la mayor formación de monómeros tras la\n\nadministración subcutánea. En conjunto, estos cambios estructurales favorecen la disociación de las moléculas de insulina, lo que se traduce en una absorción facilitada, más rápida, después de su administración en el tejido celular subcutáneo.\n\n| Tabla 8. Perfil farmacocinético de las insulinas |  |  |  |\n|---|---|---|---|\n| | Inicio | Pico | Duración eficaz |\n| Insulina lispro, aspart, glulisina | 5-15 min | 45-75 min | 2-4 h |\n| Insulina regular | ~30 min | 2-4 h | 5-8 h |\n| Insulina NPH | ~2 h | 6-10 h | 10-16 h |\n| Insulina detemir | ~2 h | Sin pico | 12-20 h |\n| Insulina glargina | ~2 h | Sin pico | 20-24 h |\n| Insulina glargina U-300 | 2-4 h | Sin pico | 24-30 h |\n| Insulina degludec | 2-4 h | Sin pico | Hasta 42 h |\n\nAdaptado de: Manual SEEN de Endocrinología. Disponible en: http://www.seen.es/manualSeen/manual.aspx (acceso 14 de marzo de 2019).\n\nLos AIAR lispro, aspart y glulisina tienen propiedades farmacocinéticas y farmacodinámicas bastante similares (tabla 8). En general, la inyección de los AIAR da lugar a una concentración máxima mayor y en la mitad de tiempo que la insulina regular humana (IRH). Los AIAR frente a la IRH reducen más eficazmente las excursiones glucémicas posprandiales (diferencia entre la glucemia preprandial y la glucemia posprandial de 1,5-2 h) y disminuyen el riesgo de hipoglucemia tardía (antes de la siguiente ingesta). Además, la rapidez de acción de los AIAR permite una administración justo antes de la ingesta o incluso después, frente a la IRH que requiere idealmente una administración previa antes de las comidas para conseguir los mejores resultados.\n\nRecientemente se han comercializado análogos de insulina ultrarrápidos (faster aspart) y existen otros en desarrollo (lispro ultrarrápida, lispro biochaperona), los cuales presentan un inicio de absorción de insulina aún más precoz y una mayor acción de insulina en las primeras 2 h, lo que se traduce en un mejor control precoz de la glucemia posprandial, y que podrían ofrecer ventajas en determinados grupos de pacientes.\n\nReferencias:\n• Manual SEEN endocrinología. Disponible en: http://www.seen.es/manualSeen/manual.aspx (acceso 14 de marzo de 2019).\n---\nDIABETES 2\n\n68. En relación con las complicaciones del tratamiento insulínico en la DM1, indique cuál de las siguientes afirmaciones es falsa:\n\nA. Las hipoglucemias son más frecuentes al intensificar el tratamiento.\nB. Los pacientes en tratamiento insulínico intensivo presentan menor ganancia de peso que con el convencional.\nC. Una mejoría rápida del control glucémico al iniciar tratamiento intensivo puede causar un empeoramiento transitorio de una retinopatía preexistente.\nD. Debe evitarse la inyección de insulina en zonas de\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}